Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Fundamental data now powered by FactSet with hourly updates!

OCGN | Ocugen Inc

Index- P/E- EPS (ttm)-0.37 Insider Own2.31% Shs Outstand256.49M Perf Week0.78%
Market Cap103.39M Forward P/E- EPS next Y-0.29 Insider Trans3.50% Shs Float250.55M Perf Month-12.29%
Income-83.28M PEG- EPS next Q-0.07 Inst Own19.06% Short Float / Ratio9.71% / 6.46 Perf Quarter-23.13%
Sales0.00M P/S- EPS this Y17.11% Inst Trans-2.91% Short Interest24.33M Perf Half Y-54.32%
Book/sh0.27 P/B1.47 EPS next Y6.35% ROA-76.04% Target Price4.12 Perf Year-77.85%
Cash/sh0.28 P/C1.46 EPS next 5Y- ROE-90.34% 52W Range0.39 - 2.09 Perf YTD-68.99%
Dividend- P/FCF- EPS past 5Y63.63% ROI-110.96% 52W High-80.70% Beta3.87
Dividend %- Quick Ratio5.46 Sales past 5Y-20.00% Gross Margin- 52W Low3.36% ATR0.02
Employees84 Current Ratio5.46 Sales Q/Q- Oper. Margin0.00% RSI (14)38.12 Volatility2.81% 4.71%
OptionableYes Debt/Eq0.09 EPS Q/Q-6.65% Profit Margin- Rel Volume0.26 Prev Close0.41
ShortableYes LT Debt/Eq0.07 EarningsAug 21 AMC Payout- Avg Volume3.76M Price0.40
Recom1.00 SMA20-3.64% SMA50-15.88% SMA200-48.92% Volume635,877 Change-0.89%
Date Action Analyst Rating Change Price Target Change
Mar-01-23Upgrade Chardan Capital Markets Neutral → Buy $3.50
Aug-23-22Initiated Mizuho Buy $5
Jun-15-22Resumed ROTH Capital Buy $8
Jun-02-22Initiated Cantor Fitzgerald Overweight $4.50
Jul-26-21Initiated Noble Capital Markets Outperform
Jun-11-21Downgrade ROTH Capital Buy → Neutral $10 → $6
May-07-21Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-09-21Downgrade Chardan Capital Markets Buy → Neutral $0.70 → $13
Feb-04-21Upgrade H.C. Wainwright Neutral → Buy $4.50
Sep-27-23 07:30PM
Sep-21-23 07:30AM
Sep-20-23 08:00AM
Sep-13-23 08:15AM
Sep-12-23 07:30PM
09:48AM Loading…
Aug-24-23 09:48AM
Aug-23-23 02:05AM
Aug-22-23 12:00PM
Aug-21-23 04:32PM
Aug-18-23 04:39PM
Jul-25-23 08:58PM
Jul-13-23 07:00AM
Jun-30-23 08:00AM
Jun-09-23 04:05PM
Jun-05-23 07:02AM
02:00PM Loading…
May-25-23 02:00PM
May-24-23 08:36AM
May-23-23 04:01PM
May-05-23 03:00PM
Apr-28-23 07:00AM
Apr-27-23 07:25AM
Apr-26-23 06:30AM
Apr-20-23 08:00AM
Apr-14-23 01:47PM
Apr-11-23 06:20PM
Mar-31-23 08:15AM
08:00AM Loading…
Mar-27-23 08:00AM
Mar-07-23 08:00AM
Mar-06-23 07:02AM
Mar-02-23 07:02AM
Mar-01-23 06:16AM
Feb-28-23 06:04PM
Feb-27-23 05:57PM
Feb-17-23 08:00AM
Feb-16-23 05:30AM
Feb-15-23 04:30PM
Feb-04-23 05:30AM
Feb-03-23 11:18AM
Feb-01-23 01:55PM
Jan-31-23 08:00AM
Jan-29-23 07:00AM
Jan-26-23 05:21AM
Jan-23-23 05:21AM
Jan-11-23 07:03AM
Jan-09-23 08:33AM
Dec-29-22 03:39PM
Dec-25-22 03:58PM
Dec-16-22 06:30AM
Dec-15-22 05:15PM
Dec-13-22 08:00AM
Dec-07-22 08:00AM
Nov-28-22 07:30AM
Nov-17-22 09:23AM
Nov-09-22 06:16PM
Nov-08-22 06:30PM
Nov-07-22 08:17AM
Nov-02-22 05:21AM
Nov-01-22 07:42PM
Oct-27-22 07:30AM
Oct-19-22 07:30AM
Oct-12-22 05:37PM
Oct-06-22 09:25AM
Sep-29-22 07:30AM
Sep-28-22 12:28PM
Sep-16-22 05:07PM
Sep-14-22 06:30AM
Sep-08-22 07:30AM
Sep-06-22 07:30AM
Sep-01-22 06:28PM
Aug-24-22 03:36PM
Aug-23-22 09:08AM
Aug-13-22 09:45AM
Aug-12-22 10:30AM
Aug-06-22 05:31AM
Aug-05-22 07:30AM
Aug-03-22 05:06PM
Jul-29-22 03:27PM
Jul-14-22 12:30PM
Jul-13-22 12:25PM
Jul-12-22 11:20AM
Jul-08-22 04:48PM
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Zhang JungeDirectorJun 14Buy0.50200,27899,9991,077,182Jun 16 04:22 PM
Musunuri ShankarChief Executive OfficerFeb 16Option Exercise0.33100,00033,0002,290,073Feb 17 05:11 PM
Musunuri ShankarChief Executive OfficerFeb 16Sale1.08100,000108,0002,190,073Feb 17 05:11 PM
Musunuri ShankarChief Executive OfficerJan 17Option Exercise0.51100,00051,0002,327,950Jan 19 04:12 PM
Musunuri ShankarChief Executive OfficerJan 17Sale1.28100,000128,0002,227,950Jan 19 04:12 PM
Musunuri ShankarChief Executive OfficerDec 16Option Exercise0.5195,80948,863848,349Dec 20 04:07 PM
Musunuri ShankarChief Executive OfficerDec 16Sale1.4395,809137,007752,540Dec 20 04:07 PM
Musunuri ShankarChief Executive OfficerOct 14Option Exercise0.51100,00051,000852,540Oct 14 04:15 PM
Musunuri ShankarChief Executive OfficerOct 14Sale1.66100,000166,000752,540Oct 14 04:15 PM
Kumar RameshDirectorOct 06Option Exercise0.514,5002,2954,500Oct 07 04:06 PM
Kumar RameshDirectorOct 06Sale1.834,5008,2350Oct 07 04:06 PM